Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | SCN10A | Q9Y5Y9 | 7/20 | 0.47 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.47 |
| ▸ | PNLIP | P16233 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31344025 | 1.00 | KMT2A (0.51) | KMT2AATMSCN10ASCN8APNLIP | |
| SCHEMBL31344132 | 0.92 | KMT2A (0.53) | KMT2AATMSCN10ASCN8APNLIP | |
| SCHEMBL31344088 | 0.92 | SORT1 (0.51) | KMT2AATMSCN10ASCN8APNLIP | |
| SCHEMBL23356160 | 0.92 | SORT1 (0.51) | KMT2AATMSCN10ASCN8APNLIP | |
| SCHEMBL23356269 | 0.92 | KMT2A (0.53) | KMT2AATMSCN10ASCN8APNLIP | |
| SCHEMBL23356260 | 0.89 | KMT2A (0.51) | KMT2AATMSCN10ASCN8APNLIP | |
| SCHEMBL31344113 | 0.89 | KMT2A (0.51) | KMT2AATMSCN10ASCN8APNLIP | |
| SCHEMBL23356277 | 0.88 | KMT2A (0.51) | KMT2AATMSCN10ASCN8APNLIP | |
| SCHEMBL29737669 | 0.88 | KMT2A (0.51) | KMT2AATMSCN10ASCN8APNLIP | |
| SCHEMBL23356327 | 0.87 | KMT2A (0.53) | KMT2AATMSCN10ASCN8APNLIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2026-01-01 | — | — | US | claimed |
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2022-07-21 | — | — | US | claimed |
| EP-3820866-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| CN-112689633-A | For inhibiting Nav1.8 pyridine carboxamide Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | claimed |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INST INC (US) | 2026-01-01 | — | — | US | disclosed |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | LIEBER INSTITUTE, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | LIEBER INSTITUTE, INC | 2022-07-21 | — | — | US | disclosed |
| EP-3820866-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | Lieber Institute, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| CN-112689633-A | For inhibiting Nav1.8 pyridine carboxamide Compounds | 利伯研究所公司 | 2021-04-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220227732-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN2A | KMT2A 1228/4885ATM 4626/4885SCN10A 4/4885 |
| US-12234221-B2 | Pyridine carboxamide compounds for inhibiting NAV1.8 | SCN8A, SCN1A, SCN2A | KMT2A 1228/4885ATM 4626/4885SCN10A 4/4885 |
| US-20260001861-A1 | PYRIDINE CARBOXAMIDE COMPOUNDS FOR INHIBITING NAV1.8 | SCN8A, SCN1A, SCN1B | KMT2A 2792/4885ATM 4836/4885SCN10A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.